Loading tape…Loading tape…
REGN
REGN
REGN
Regeneron Pharmaceuticals announced it will report its third quarter 2026 financial and operating results on October 30, 2026. Heading into the earnings release, the company carries a market capitalization of $85.27 billion, full-year revenue of $14.34 billion, and a TTM EPS of 41.86. Investors will also be watching key valuation metrics, including its PE ratio of 19.76 and a free cash flow yield of 4.13%.
Based on globenewswire.comLibtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
2,281 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by First Citizens Bank & Trust Co.
Here Are Thursday’s Top Wall Street Analyst Research Calls: AngloGold Ashanti, Bank of America, Cirrus Logic, Crocs, Diamondback Energy, Devon Energy, Netflix, PayPal, Spotify Technolgy , and More
Longleaf Partners Global Fund Q3 2026 Portfolio Review
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Longleaf Partners Fund Q3 2026 Portfolio Review
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.